ANKRD2 and osteosarcoma: Our observations further revealed that OS cells devoid of Ankrd2 showed an increased sensibility to doxorubicin and cisplatin, two of the most common chemotherapeutic drugs used in the treatment of osteosarcoma and other malignancies.